Full Press Release Details
Ultragenyx and Kyowa Kirin Announce U.S. FDA Approves Label Update for Crysvita (burosumab) for the Treatment of X-Linked Hypophosphatemia (XLH).
RARE
Ultragenyx and Kyowa Kirin Announce U.S. FDA Approves Label Update for Crysvita (burosumab) for the Treatment of X-Linked Hypophosphatemia (XLH)
Key Takeaway: Ultragenyx and Kyowa Kirin Announce U.S. FDA Approves Label Update for Crysvita (burosumab) for the Treatment of X-Linked Hypophosphatemia (XLH)